BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 31934893)

  • 21. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
    Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
    Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNAs in Barrett's esophagus and esophageal adenocarcinoma.
    Kan T; Meltzer SJ
    Curr Opin Pharmacol; 2009 Dec; 9(6):727-32. PubMed ID: 19773200
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus.
    Maru DM; Singh RR; Hannah C; Albarracin CT; Li YX; Abraham R; Romans AM; Yao H; Luthra MG; Anandasabapathy S; Swisher SG; Hofstetter WL; Rashid A; Luthra R
    Am J Pathol; 2009 May; 174(5):1940-8. PubMed ID: 19342367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of dysplasia in patients with Barrett's esophagus based on expression pattern of 90 genes.
    Varghese S; Newton R; Ross-Innes CS; Lao-Sirieix P; Krishnadath KK; O'Donovan M; Novelli M; Wernisch L; Bergman J; Fitzgerald RC
    Gastroenterology; 2015 Nov; 149(6):1511-1518.e5. PubMed ID: 26248086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic profiles of Barrett's esophagus and esophageal adenocarcinoma in Japanese patients.
    Tokunaga M; Okimoto K; Akizue N; Ishikawa K; Hirotsu Y; Amemiya K; Ota M; Matsusaka K; Nishimura M; Matsushita K; Ishikawa T; Nagashima A; Shiratori W; Kaneko T; Oura H; Kanayama K; Ohta Y; Taida T; Saito K; Matsumura T; Chiba T; Mochizuki H; Arai M; Kato J; Ikeda JI; Omata M; Kato N
    Sci Rep; 2021 Sep; 11(1):17671. PubMed ID: 34480065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
    Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
    Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia.
    Duits LC; van der Wel MJ; Cotton CC; Phoa KN; Ten Kate FJW; Seldenrijk CA; Offerhaus GJA; Visser M; Meijer SL; Mallant-Hent RC; Krishnadath KK; Pouw RE; Tijssen JGP; Shaheen NJ; Bergman JJGHM
    Gastroenterology; 2017 Apr; 152(5):993-1001.e1. PubMed ID: 28012849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vitamin D receptor is highly expressed in precancerous lesions and esophageal adenocarcinoma with significant sex difference.
    Zhou Z; Xia Y; Bandla S; Zakharov V; Wu S; Peters J; Godfrey TE; Sun J
    Hum Pathol; 2014 Aug; 45(8):1744-51. PubMed ID: 24951052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett's esophageal carcinogenesis.
    Leidner RS; Ravi L; Leahy P; Chen Y; Bednarchik B; Streppel M; Canto M; Wang JS; Maitra A; Willis J; Markowitz SD; Barnholtz-Sloan J; Adams MD; Chak A; Guda K
    Genes Chromosomes Cancer; 2012 May; 51(5):473-9. PubMed ID: 22302717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Systematic Review of Esophageal MicroRNA Markers for Diagnosis and Monitoring of Barrett's Esophagus.
    Mallick R; Patnaik SK; Wani S; Bansal A
    Dig Dis Sci; 2016 Apr; 61(4):1039-50. PubMed ID: 26572780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of Mutational Testing of Preneoplastic Barrett's Mucosa by Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Endoscopic Samples for Detection of Concurrent Dysplasia and Adenocarcinoma in Barrett's Esophagus.
    Del Portillo A; Lagana SM; Yao Y; Uehara T; Jhala N; Ganguly T; Nagy P; Gutierrez J; Luna A; Abrams J; Liu Y; Brand R; Sepulveda JL; Falk GW; Sepulveda AR
    J Mol Diagn; 2015 Jul; 17(4):412-9. PubMed ID: 26068095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence].
    Mokrowiecka A; Wierzchniewska-Ławska A; Smolarz B; Romanowicz-Makowska H; Malecka-Panas E
    Pol Merkur Lekarski; 2009 May; 26(155):385-9. PubMed ID: 19606680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MiRNA-Related SNPs and Risk of Esophageal Adenocarcinoma and Barrett's Esophagus: Post Genome-Wide Association Analysis in the BEACON Consortium.
    Buas MF; Onstad L; Levine DM; Risch HA; Chow WH; Liu G; Fitzgerald RC; Bernstein L; Ye W; Bird NC; Romero Y; Casson AG; Corley DA; Shaheen NJ; Wu AH; Gammon MD; Reid BJ; Hardie LJ; Peters U; Whiteman DC; Vaughan TL
    PLoS One; 2015; 10(6):e0128617. PubMed ID: 26039359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. From genetics to signaling pathways: molecular pathogenesis of esophageal adenocarcinoma.
    Caspa Gokulan R; Garcia-Buitrago MT; Zaika AI
    Biochim Biophys Acta Rev Cancer; 2019 Aug; 1872(1):37-48. PubMed ID: 31152823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma.
    Akagi T; Ito T; Kato M; Jin Z; Cheng Y; Kan T; Yamamoto G; Olaru A; Kawamata N; Boult J; Soukiasian HJ; Miller CW; Ogawa S; Meltzer SJ; Koeffler HP
    Int J Cancer; 2009 Nov; 125(10):2349-59. PubMed ID: 19670330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Profiling of circulating microRNAs in patients with Barrett's esophagus and esophageal adenocarcinoma.
    Bus P; Kestens C; Ten Kate FJ; Peters W; Drenth JP; Roodhart JM; Siersema PD; van Baal JW
    J Gastroenterol; 2016 Jun; 51(6):560-70. PubMed ID: 26585599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isoforms of RNF128 Regulate the Stability of Mutant P53 in Barrett's Esophageal Cells.
    Ray D; Ray P; Ferrer-Torres D; Wang Z; Nancarrow D; Yoon HW; San Martinho M; Hinton T; Owens S; Thomas D; Jiang H; Lawrence TS; Lin J; Lagisetty K; Chang AC; Beer DG
    Gastroenterology; 2020 Feb; 158(3):583-597.e1. PubMed ID: 31715145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus.
    Bird-Lieberman EL; Dunn JM; Coleman HG; Lao-Sirieix P; Oukrif D; Moore CE; Varghese S; Johnston BT; Arthur K; McManus DT; Novelli MR; O'Donovan M; Cardwell CR; Lovat LB; Murray LJ; Fitzgerald RC
    Gastroenterology; 2012 Oct; 143(4):927-35.e3. PubMed ID: 22771507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression analysis of Barrett's esophagus-associated high-grade dysplasia in laser capture microdissected archival tissue.
    Sabo E; Meitner PA; Tavares R; Corless CL; Lauwers GY; Moss SF; Resnick MB
    Clin Cancer Res; 2008 Oct; 14(20):6440-8. PubMed ID: 18927283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.